TY - JOUR ID - 40613 TI - Intralesional Injection of the Measles–Mumps–Rubella Vaccine into Resistant Palmoplantar Warts: A Randomized Controlled Trial JO - Iranian Journal of Medical Sciences JA - IJMS LA - en SN - 0253-0716 AU - Rezai, Mohammad Sadegh AU - Ghasempouri, Hiva AU - Asqary Marzidareh, Ozra AU - Yazdani Cherati, Jamshid AU - Rahmatpour Rokni, Ghasem AD - Pediatric Infectious Diseases Superspecialist, Infectious Diseases Research Center with focus on Nosocomial Infections, Mazandaran University of Medical Sciences, Sari, Ira AD - General physician, Mazandaran University of Medical Sciences, Sari, Iran AD - Epidemiologist, Department of Biostatistics, Health Sciences Research Center, Mazandaran University of Medical Sciences, Sari, Iran AD - General physician, Mazandaran University of Medical Sciences, Sari, Iran and Dermatologist, Clinical Research Development Unit of Bou-Ali Sina Hospital, Mazandaran University of Medical Sciences, Sari, Iran Y1 - 2019 PY - 2019 VL - 44 IS - 1 SP - 10 EP - 17 KW - Injections KW - Intralesional KW - Measles–mumps–rubella vaccine KW - Warts DO - 10.30476/ijms.2019.40613 N2 - Background: Common resistant-to-therapy warts pose a challenge to both clinicians and patients. Among many destructive and immunotherapeutic options, no single, fully effective treatment has been suggested yet. Many investigations, including those using intralesional antigen administrations, have demonstrated that cellular immunity plays a major role in the clearance of human papilloma virus (HPV) infection. The aim of the present study was to evaluate the effects of the intralesional injection of the measles–mumps–rubella (MMR) vaccine into resistant-to- treatment palmoplantar warts and its complications.Methods: In this single-blind, randomized, controlled clinical trial, 60 cases with resistant-to-therapy palmoplantar warts referring to the Dermatology Clinic of Bou-Ali Sina Hospital of Sari between June 2015 and 2016 were randomly assigned to 2 equal groups: the MMR Group received intralesional MMR and the Placebo Group was given saline injection. The injections were administered at 2-week intervals until complete clearance was achieved or for a maximum of 5 injections ( UR - https://ijms.sums.ac.ir/article_40613.html L1 - https://ijms.sums.ac.ir/article_40613_40a6b824003448046e4f8c79fad2037e.pdf ER -